Floatz logo

Wellbutrin

Lung Non-Small Cell Carcinoma

Thomas Jefferson UniversityPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
FLUDEOXYGLUCOSE
Alliance for Clinical Trials in Oncology
Phase 3BB
Montanide Isa 51
Roswell Park Cancer Institute
Phase 3BB
Recombinant Human EGF-rP64K
Roswell Park Cancer Institute
Phase 2BB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BB
MITOMYCIN C
City of Hope Medical Center
Phase 3B

View all 24 →

Same molecule, other indications

Wellbutrin is also rated in:

Smoking CessationDormant
A
Indicative ·
82 / 100
View asset →
DysthymiaDormant
BBB
Indicative ·
73 / 100
View asset →
depressive disorderDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →